Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Measuring Competency of Pharmacy Residents: A Survey of Residency Programs' Methods for Assessment and Evaluation.

Kary SJ, Dumont Z, Tangedal K, Bolt J, Semchuk WM.

Can J Hosp Pharm. 2019 Sep-Oct;72(5):343-352. Epub 2019 Oct 21.

PMID:
31692605
2.

Transient Ischemic Attack in a High-Risk Cardiovascular Patient with Renal Dysfunction after Treatment with Rivaroxaban and Clopidogrel: A Case Report.

Kary SJ, Roy CJ, Semchuk WM, Lavoie AJ.

Can J Hosp Pharm. 2019 Jan-Feb;72(1):49-51. Epub 2018 Feb 28. No abstract available.

3.

The small RNA RssR regulates myo-inositol degradation by Salmonella enterica.

Kröger C, Rothhardt JE, Brokatzky D, Felsl A, Kary SC, Heermann R, Fuchs TM.

Sci Rep. 2018 Dec 10;8(1):17739. doi: 10.1038/s41598-018-35784-8.

4.

Negative supercoiling of DNA by gyrase is inhibited in Salmonella enterica serovar Typhimurium during adaptation to acid stress.

Colgan AM, Quinn HJ, Kary SC, Mitchenall LA, Maxwell A, Cameron ADS, Dorman CJ.

Mol Microbiol. 2018 Mar;107(6):734-746. doi: 10.1111/mmi.13911. Epub 2018 Feb 5.

5.

Small RNA, Big Effect: Control of Flagellin Production.

Miranda-CasoLuengo AA, Kary SC, Erhardt M, Kröger C.

Trends Microbiol. 2017 Dec;25(12):953-954. doi: 10.1016/j.tim.2017.10.003. Epub 2017 Oct 30.

PMID:
29097088
6.

The Global Regulatory Cyclic AMP Receptor Protein (CRP) Controls Multifactorial Fluoroquinolone Susceptibility in Salmonella enterica Serovar Typhimurium.

Kary SC, Yoneda JRK, Olshefsky SC, Stewart LA, West SB, Cameron ADS.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01666-17. doi: 10.1128/AAC.01666-17. Print 2017 Nov.

7.

Genetic Regulation of Virulence and Antibiotic Resistance in Acinetobacter baumannii.

Kröger C, Kary SC, Schauer K, Cameron AD.

Genes (Basel). 2016 Dec 28;8(1). pii: E12. doi: 10.3390/genes8010012. Review.

8.

Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab.

van der Heijde D, Breban M, Halter D, DiVittorio G, Bratt J, Cantini F, Kary S, Pangan AL, Kupper H, Rathmann SS, Sieper J, Mease PJ.

Rheumatology (Oxford). 2015 Jul;54(7):1210-9. doi: 10.1093/rheumatology/keu438. Epub 2014 Dec 25.

9.

Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study.

Burmester GR, Matucci-Cerinic M, Mariette X, Navarro-Blasco F, Kary S, Unnebrink K, Kupper H.

Arthritis Res Ther. 2014 Jan 27;16(1):R24. doi: 10.1186/ar4452.

10.

Transmission of an oxygen availability signal at the Salmonella enterica serovar Typhimurium fis promoter.

Cameron AD, Kröger C, Quinn HJ, Scally IK, Daly AJ, Kary SC, Dorman CJ.

PLoS One. 2013 Dec 16;8(12):e84382. doi: 10.1371/journal.pone.0084382. eCollection 2013.

11.

Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT.

Mease PJ, Heckaman M, Kary S, Kupper H.

J Rheumatol. 2013 May;40(5):647-52. doi: 10.3899/jrheum.120970. Epub 2013 Mar 15.

12.

Murine diacylglycerol acyltransferase-2 (DGAT2) can catalyze triacylglycerol synthesis and promote lipid droplet formation independent of its localization to the endoplasmic reticulum.

McFie PJ, Banman SL, Kary S, Stone SJ.

J Biol Chem. 2011 Aug 12;286(32):28235-46. doi: 10.1074/jbc.M111.256008. Epub 2011 Jun 16.

13.

Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.

Rudwaleit M, Van den Bosch F, Kron M, Kary S, Kupper H.

Arthritis Res Ther. 2010;12(3):R117. doi: 10.1186/ar3054. Epub 2010 Jun 16.

14.

Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis.

Braun J, Rudwaleit M, Kary S, Kron M, Wong RL, Kupper H.

Rheumatology (Oxford). 2010 Aug;49(8):1578-89. doi: 10.1093/rheumatology/keq129. Epub 2010 May 6.

PMID:
20448079
15.

Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis.

Rudwaleit M, Claudepierre P, Kron M, Kary S, Wong R, Kupper H.

Arthritis Res Ther. 2010;12(2):R43. doi: 10.1186/ar2953. Epub 2010 Mar 15.

16.

Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions.

Van den Bosch F, Manger B, Goupille P, McHugh N, Rødevand E, Holck P, van Vollenhoven RF, Leirisalo-Repo M, Fitzgerald O, Kron M, Frank M, Kary S, Kupper H.

Ann Rheum Dis. 2010 Feb;69(2):394-9. doi: 10.1136/ard.2009.111856. Epub 2009 Oct 7.

17.

Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis.

Rudwaleit M, Claudepierre P, Wordsworth P, Cortina EL, Sieper J, Kron M, Carcereri-De-Prati R, Kupper H, Kary S.

J Rheumatol. 2009 Apr;36(4):801-8. doi: 10.3899/jrheum.081048. Epub 2009 Feb 27.

PMID:
19273449
18.

Adalimumab is effective and well tolerated in treating patients with ankylosing spondylitis who have advanced spinal fusion.

Rudwaleit M, Olivieri I, Boki KA, Griep EN, Järvinen P, Wong RL, Kron M, Kary S, Kupper H.

Rheumatology (Oxford). 2009 May;48(5):551-7. doi: 10.1093/rheumatology/kep022. Epub 2009 Mar 1.

PMID:
19254918
19.

Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study.

Rudwaleit M, Rødevand E, Holck P, Vanhoof J, Kron M, Kary S, Kupper H.

Ann Rheum Dis. 2009 May;68(5):696-701. doi: 10.1136/ard.2008.092585. Epub 2008 Jul 28.

20.

An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status.

van der Bijl AE, Breedveld FC, Antoni CE, Kalden JR, Kary S, Burmester GR, Beckmann C, Unnebrink K, Kupper H.

Clin Rheumatol. 2008 Aug;27(8):1021-8. doi: 10.1007/s10067-008-0866-4. Epub 2008 Mar 19.

21.

Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study.

Burmester GR, Ferraccioli G, Flipo RM, Monteagudo-Sáez I, Unnebrink K, Kary S, Kupper H.

Arthritis Rheum. 2008 Jan 15;59(1):32-41. doi: 10.1002/art.23247.

22.

Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.

Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, Oezer U, Kary S, Kupper H, Burmester GR; Research in Active Rheumatoid Arthritis (ReAct) Study Group.

Rheumatology (Oxford). 2007 Jul;46(7):1191-9. Epub 2007 May 15.

PMID:
17504821
23.

Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.

Burmester GR, Mariette X, Montecucco C, Monteagudo-Sáez I, Malaise M, Tzioufas AG, Bijlsma JW, Unnebrink K, Kary S, Kupper H.

Ann Rheum Dis. 2007 Jun;66(6):732-9. Epub 2007 Feb 28.

24.

Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.

Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Röwert J, Audring H, Kary S, Burmester GR, Sterry W, Worm M.

Br J Dermatol. 2007 Mar;156(3):486-91.

PMID:
17300238
25.

Sonography of postexcision specimens of nonpalpable breast lesions: value, limitations, and description of a method.

Mesurolle B, El-Khoury M, Hori D, Phancao JP, Kary S, Kao E, Fleiszer D.

AJR Am J Roentgenol. 2006 Apr;186(4):1014-24.

PMID:
16554572
26.

Infections in patients with rheumatoid arthritis treated with biologic agents.

Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, Gromnica-Ihle E, Antoni C, Herzer P, Kekow J, Schneider M, Zink A.

Arthritis Rheum. 2005 Nov;52(11):3403-12.

27.

New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists.

Kary S, Worm M, Audring H, Huscher D, Renelt M, Sörensen H, Ständer E, Maass U, Lee H, Sterry W, Burmester GR.

Ann Rheum Dis. 2006 Mar;65(3):405-7. Epub 2005 Sep 8.

28.

Treatment continuation in patients receiving biological agents or conventional DMARD therapy.

Zink A, Listing J, Kary S, Ramlau P, Stoyanova-Scholz M, Babinsky K, von Hinueber U, Gromnica-Ihle E, Wassenberg S, Antoni C, Herzer P, Kekow J, Schneider M, Rau R.

Ann Rheum Dis. 2005 Sep;64(9):1274-9. Epub 2005 Feb 11.

29.

Do we still miss the chance of effectively treating early rheumatoid arthritis? New answers from a new study.

Kary S, Fritz J, Scherer HU, Burmester GR.

Rheumatology (Oxford). 2004 Jul;43(7):819-20. Epub 2004 Jun 8. No abstract available.

PMID:
15187247
30.

[Pharmacotherapy of rheumatic diseases in the aged].

Kary S, Buttgereit F, Burmester GR.

Internist (Berl). 2003 Aug;44(8):951-8. Review. German.

PMID:
14671809
31.

Anakinra: the first interleukin-1 inhibitor in the treatment of rheumatoid arthritis.

Kary S, Burmester GR.

Int J Clin Pract. 2003 Apr;57(3):231-4. Review.

PMID:
12723729
32.

Therapie der rheumatoiden Arthritis bei Erwachsenen mit Biologika.

Kary S, Burmester GR.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2002 Sep;45(9):671-6. doi: 10.1007/s00103-002-0452-x. German.

PMID:
24728115
33.

Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial.

Sieper J, Kary S, Sörensen H, Alten R, Eggens U, Hüge W, Hiepe F, Kühne A, Listing J, Ulbrich N, Braun J, Zink A, Mitchison NA.

Arthritis Rheum. 1996 Jan;39(1):41-51.

PMID:
8546737
34.

Toxicological aspects of activated sludge feeding.

Nachtomi E, Lipstein B, Kary S.

Bull Environ Contam Toxicol. 1989 Dec;43(6):879-85. No abstract available.

PMID:
2597792

Supplemental Content

Support Center